{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:29:15Z","timestamp":1794047355509,"version":"4.8.0"},"reference-count":34,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"4","license":[{"start":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T00:00:00Z","timestamp":1586390400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Plasmablastic lymphoma mutational profile is undescribed. Here we performed a targeted exonic NGS analysis of 30 plasmablastic lymphoma cases with a B cell lymphoma dedicated panel and FISH for the detection of MYC rearrangements. A complete phenotyping of the neoplastic and microenvironment cell populations was also performed. We have identified an enrichment in recurrent genetic events in MYC (69% with MYC translocation or amplification and 3 cases with missense point mutations), PRDM1\/Blimp1 and STAT3 mutations. These gene mutations were more frequent in EBV positive disease. Other genetic events included mutations in BRAF, EP300, BCR (CD79A and CD79B), NOTCH pathway (NOTCH2, NOTCH1 and SGK1) and MYD88pL265P. Immunohistochemical analysis showed consistent MYC expression, higher in cases with MYC rearrangements together with phospho-STAT3 (Tyr705) overexpression in cases with STAT3 SH2 domain mutations. Microenvironment populations were heterogeneous and unrelated with EBV, with an enrichment of Tumor Associated Macrophages (TAM) and PD1 positive T cells. PD-L1 was expressed in all cases in the TAM population but only in 5 cases in the neoplastic cells (4 out of 14 EBV positive cases). HLA expression was absent in the majority of PBL cases. In summary, Plasmablastic lymphoma mutational profile is heterogeneous and related with EBV infection. Genetic events in MYC, STAT3 and PRDM1\/Blimp1 are more frequent in EBV positive disease. An enrichment in TAM and PD1 reactive T lymphocytes is found in the microenvironment of PBL cases, that express PD-L1 in the neoplastic cells in a fraction of cases.<\/jats:p>","DOI":"10.3324\/haematol.2020.251579","type":"journal-article","created":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T16:15:15Z","timestamp":1586448915000},"page":"1120-1128","source":"Crossref","is-referenced-by-count":51,"title":["Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma"],"prefix":"10.3324","volume":"106","author":[{"family":"Julia Garcia-Reyero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Nerea Martinez Magunacelaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Sonia Gonzalez de Villambrosia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Sanam Loghavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Angela Gomez Mediavilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Raul Tonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Sergi Beltran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Marta Gut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Ainara Pere\u00f1a Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Emanuele d'\u00c1more","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Carlo Visco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Joseph D. Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Santiago Montes-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2020,4,9]]},"reference":[{"key":"24237","unstructured":"Swerdlow S, Campo E, Harris NL. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Fourth edition. IARC. 2008."},{"key":"24238","doi-asserted-by":"crossref","unstructured":"Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011; 117(19):5019-5032.","DOI":"10.1182\/blood-2011-01-293050"},{"key":"24239","doi-asserted-by":"crossref","unstructured":"Delecluse HJ, Anagnostopoulos I, Dallenbach F. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood. 1997; 89(4):1413-1420.","DOI":"10.1182\/blood.V89.4.1413"},{"key":"24240","doi-asserted-by":"crossref","unstructured":"Montes-Moreno S, Gonzalez-Medina AR, Rodriguez-Pinilla SM. Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype. Haematologica. 2010; 95(8):1342-1349.","DOI":"10.3324\/haematol.2009.016113"},{"key":"24241","doi-asserted-by":"crossref","unstructured":"Colomo L, Loong F, Rives S. Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities. Am J Surg Pathol. 2004; 28(6):736-747.","DOI":"10.1097\/01.pas.0000126781.87158.e3"},{"key":"24242","doi-asserted-by":"crossref","unstructured":"Chapman J, Gentles AJ, Sujoy V. Gene expression analysis of plasmablastic lymphoma identifies downregulation of B-cell receptor signaling and additional unique transcriptional programs. Leukemia. 2015; 29(11):2270-2273.","DOI":"10.1038\/leu.2015.109"},{"key":"24243","doi-asserted-by":"crossref","unstructured":"Gravelle P, P\u00e9ricart S, Tosolini M. EBV infection determines the immune hallmarks of plasmablastic lymphoma. Oncoimmunology. 2018; 7(10):e1486950.","DOI":"10.1080\/2162402X.2018.1486950"},{"key":"24244","doi-asserted-by":"crossref","unstructured":"Laurent C, Fabiani B, Do C. Immunecheckpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients. Haematologica. 2016; 101(8):976-984.","DOI":"10.3324\/haematol.2016.141978"},{"key":"24245","doi-asserted-by":"crossref","unstructured":"Schmelz M, Montes-Moreno S, Piris M, Wilkinson ST, Rimsza LM. Lack and\/or aberrant localization of major histocompatibility class II (MHCII) protein in plasmablastic lymphoma. Haematologica. 2012; 97(10):1614-1616.","DOI":"10.3324\/haematol.2011.060186"},{"key":"24246","doi-asserted-by":"crossref","unstructured":"Valera A, Balagu\u00e9 O, Colomo L. IG\/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas. Am J Surg Pathol. 2010; 34(11):1686-1694.","DOI":"10.1097\/PAS.0b013e3181f3e29f"},{"key":"24247","doi-asserted-by":"crossref","unstructured":"Taddesse-Heath L, Meloni-Ehrig A, Scheerle J, Kelly JC, Jaffe ES. Plasmablastic lymphoma with MYC translocation: evidence for a common pathway in the generation of plasmablastic features. Mod Pathol. 2010; 23(7):991-999.","DOI":"10.1038\/modpathol.2010.72"},{"key":"24248","doi-asserted-by":"crossref","unstructured":"Montes-Moreno S, Martinez-Magunacelaya N, Zecchini-Barrese T. Plasmablastic lymphoma phenotype is determined by genetic alterations in MYC and PRDM1. Mod Pathol. 2017; 30(1):85-94.","DOI":"10.1038\/modpathol.2016.162"},{"key":"24249","doi-asserted-by":"crossref","unstructured":"Munevver C, Rong HR, Chineke I. Genetic analysis of plasmablastic lymphomas in HIV (+) patients reveals novel driver regulators of the noncanonical NF-\u03baB pathway. Blood. 2018; 132(Suppl 1):1565.","DOI":"10.1182\/blood-2018-99-118351"},{"key":"24250","unstructured":"Swerdlow SH, Campo E, Harris NL. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised fourth edition. IARC. Lyon. 2017."},{"key":"24251","doi-asserted-by":"crossref","unstructured":"Montes-Moreno S, Martinez-Magunacelaya N, Zecchini-Barrese T. Plasmablastic lymphoma phenotype is determined by genetic alterations in MYC and PRDM1. Mod Pathol. 2017; 30(1):85-94.","DOI":"10.1038\/modpathol.2016.162"},{"key":"24252","doi-asserted-by":"crossref","unstructured":"Pasqualucci L, Neumeister P, Goossens T. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature. 2001; 412(6844):341-346.","DOI":"10.1038\/35085588"},{"key":"24253","doi-asserted-by":"crossref","unstructured":"Loghavi S, Alayed K, Aladily TN. Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients. J Hematol Oncol. 2015; 8:65.","DOI":"10.1186\/s13045-015-0163-z"},{"key":"24254","doi-asserted-by":"crossref","unstructured":"Sarosiek KA, Malumbres R, Nechushtan H, Gentles AJ, Avisar E, Lossos IS. Novel IL-21 signaling pathway up-regulates c-Myc and induces apoptosis of diffuse large B-cell lymphomas. Blood. 2010; 115(3):570-580.","DOI":"10.1182\/blood-2009-08-239996"},{"key":"24255","doi-asserted-by":"crossref","unstructured":"Ohgami RS, Ma L, Monabati A, Zehnder JL, Arber DA. STAT3 mutations are present in aggressive B-cell lymphomas including a subset of diffuse large B-cell lymphomas with CD30 expression. Haematologica. 2014; 99(7):e105-107.","DOI":"10.3324\/haematol.2013.101543"},{"key":"24256","doi-asserted-by":"crossref","unstructured":"Valera A, Colomo L, Martinez A. ALK-positive large B-cell lymphomas express a terminal B-cell differentiation program and activated STAT3 but lack MYC rearrangements. Mod Pathol. 2013; 26(10):1329-1337.","DOI":"10.1038\/modpathol.2013.73"},{"key":"24257","doi-asserted-by":"crossref","unstructured":"Tabanelli V, Corsini C, Fiori S. Recurrent PDL1 expression and PDL1 (CD274) copy number alterations in breast implant-associated anaplastic large cell lymphomas. Hum Pathol. 2019; 90:60-69.","DOI":"10.1016\/j.humpath.2019.05.007"},{"key":"24258","doi-asserted-by":"crossref","unstructured":"Ngo VN, Young RM, Schmitz R. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011; 470(7332):115-119.","DOI":"10.1038\/nature09671"},{"key":"24259","doi-asserted-by":"crossref","unstructured":"Chapuy B, Roemer MG, Stewart C. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016; 127(7):869-881.","DOI":"10.1182\/blood-2015-10-673236"},{"key":"24260","doi-asserted-by":"crossref","unstructured":"Treon SP, Xu L, Yang G. MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia. N Engl J Med. 2012; 367(9):826-833.","DOI":"10.1056\/NEJMoa1200710"},{"key":"24261","doi-asserted-by":"crossref","unstructured":"Davis RE, Ngo VN, Lenz G. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010; 463(7277):88-92.","DOI":"10.1038\/nature08638"},{"key":"24262","doi-asserted-by":"crossref","unstructured":"Karube K, Enjuanes A, Dlouhy I. Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets. Leukemia. 2018; 32(3):675-684.","DOI":"10.1038\/leu.2017.251"},{"key":"24263","doi-asserted-by":"crossref","unstructured":"Wang K, Zhang Q, Li D. PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a \u03b3-secretase inhibitor. Clin Cancer Res. 2015; 21(6):1487-1496.","DOI":"10.1158\/1078-0432.CCR-14-1348"},{"key":"24264","doi-asserted-by":"crossref","unstructured":"Sutton LA, Ljungstr\u00f6m V, Mansouri L. Targeted next-generation sequencing in chronic lymphocytic leukemia: a highthroughput yet tailored approach will facilitate implementation in a clinical setting. Haematologica. 2015; 100(3):370-376.","DOI":"10.3324\/haematol.2014.109777"},{"key":"24265","doi-asserted-by":"crossref","unstructured":"Mo JS, Ann EJ, Yoon JH. Serum- and glucocorticoid- inducible kinase 1 (SGK1) controls Notch1 signaling by downregulation of protein stability through Fbw7 ubiquitin ligase. J Cell Sci. 2011; 124(Pt 1):100-112.","DOI":"10.1242\/jcs.073924"},{"key":"24266","doi-asserted-by":"crossref","unstructured":"Chapman MA, Lawrence MS, Keats JJ. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011; 471(7339):467-472.","DOI":"10.1038\/nature09837"},{"key":"24267","doi-asserted-by":"crossref","unstructured":"Bohn OL, Hsu K, Hyman DM, Pignataro DS, Giralt S, Teruya-Feldstein J. BRAF V600E mutation and clonal evolution in a patient with relapsed refractory myeloma with plasmablastic differentiation. Clin Lymphoma Myeloma Leuk. 2014; 14(2):e65-68.","DOI":"10.1016\/j.clml.2013.12.003"},{"key":"24268","doi-asserted-by":"crossref","unstructured":"Andrulis M, Lehners N, Capper D. Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov. 2013; 3(8):862-869.","DOI":"10.1158\/2159-8290.CD-13-0014"},{"key":"24269","doi-asserted-by":"crossref","unstructured":"Chen BJ, Chapuy B, Ouyang J. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virusassociated malignancies. Clin Cancer Res. 2013; 19(13):3462-3473.","DOI":"10.1158\/1078-0432.CCR-13-0855"},{"key":"24270","doi-asserted-by":"crossref","unstructured":"Veloza L, Teixido C, Castrejon N. Clinicopathological evaluation of the programmed cell death 1 (PD1)\/programmed cell death-ligand 1 (PD-L1) axis in posttransplant lymphoproliferative disorders: association with Epstein-Barr virus, PD-L1 copy number alterations, and outcome. Histopathology. 2019; 75(6):799-812.","DOI":"10.1111\/his.13857"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/9710\/70751","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9710\/70752","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9710\/70751","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:56:45Z","timestamp":1794045405000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/9710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,9]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2020.251579","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4,9]]}}}